Overall, our screen in the MTAP-negative A549 NSCLC cell line showed that PARPi exhibited a high synergistic interaction with a type I PRMT inhibitor, which may be easily combined in a clinical setting to increase therapeutic efficacy (Fig. 2a–c). The gene discussed is MTAP; the disease is non-small cell lung carcinoma.